The scale of the problem the team is attacking is enormous. Alzheimer’s disease is the most common neurodegenerative disorder in the world, and as populations age, its incidence climbs every year; by 2050, the number of people living with dementia is projected to exceed 150 million. Despite decades of effort, no drug has been found that effectively reverses the disease, largely because its pathogenesis is complex and incompletely understood and its onset unfolds over many years. The pathological picture is dominated by the abnormal accumulation of amyloid-β (Aβ42), which triggers a cascade of further damage: the aggregates provoke the overproduction of reactive oxygen species (ROS), and the resulting oxidative stress is tightly entangled with neuroinflammation, synaptic dysfunction, and progressive memory loss. Because these processes feed one another, therapies that attack only a single target have struggled. Earlier nanomaterials, including protein-capped cadmium sulfide nanoparticles and a dipeptide-modified gold nanocluster that dissolved mature amyloid fibrils, showed that inorganic agents can act on protein aggregates, but many suffered from modest inhibitory efficiency and limited dissociation ability.

Hydrogen has long been an intriguing candidate for exactly this kind of multi-target problem. The biological effects of molecular hydrogen are attributed largely to its ability to selectively scavenge highly reactive oxygen species — above all the hydroxyl radical (∙OH) — without interfering with the physiologically important ROS that cells use for signaling. Its exceptional biosafety profile has been widely confirmed, and it has been explored as a treatment for numerous inflammatory conditions. The catch is delivery. Hydrogen is poorly soluble in water and diffuses rapidly, so conventional administration routes — inhaling hydrogen gas or drinking hydrogen-rich water — cannot achieve meaningful accumulation at inflammatory sites inside the brain. Worse, any molecule hoping to reach those sites must first negotiate the blood-brain barrier, the tightly sealed endothelial boundary that restricts the entry of most drugs. The authors argue that achieving sustained, in-situ release of hydrogen at the site of neuroinflammation is therefore the crucial step for turning hydrogen therapy from a promising idea into a practical treatment for Alzheimer’s disease.

The new study’s answer is to make palladium do the work. Palladium is famous among chemists for its appetite for hydrogen: hydrogen atoms can slip into the interstitial sites of its crystal lattice, giving the metal one of the highest hydrogen storage capacities of any element, and it is highly active in catalytic hydrogenation, especially at the nanoscale. The researchers first synthesized uniform palladium nanosheets by dissolving palladium(II) acetylacetone with poly(vinylpyrrolidone) and sodium bromide in a dimethylformamide–water mixture under a carbon monoxide atmosphere at 80 °C. They then bubbled hydrogen gas through the nanoparticle solution for 15 minutes, loading the sheets to form palladium hydride. Transmission electron microscopy revealed hexagonal nanosheets roughly 37 nanometers in diameter — comfortably below the 100-nanometer threshold at which inorganic nanoparticles can efficiently penetrate a wide range of tissues, including the blood-brain barrier — with good dispersion that favors storing, transferring, and releasing hydrogen. X-ray diffraction supplied the chemical proof: compared with metallic palladium, the PdH diffraction peaks shifted slightly toward smaller angles, which, according to Bragg’s law, reflects expansion of the crystal lattice as hydrogen atoms squeeze into the interstitial sites.

The same sheets turn out to be excellent light absorbers. When aqueous PdH solutions at different concentrations were irradiated with an 808-nanometer laser at 1 watt per square centimeter for five minutes — temperature changes tracked with an infrared thermal camera — the solutions heated steeply with both time and concentration, and the material showed no obvious attenuation across three repeated heating-and-cooling cycles, a sign of excellent photothermal stability. From the fitted cooling curve, the team calculated a photothermal conversion efficiency of 38.50 percent, a competitive figure for a photothermal agent. Ultraviolet-visible-near-infrared spectroscopy showed broad absorption across the 500-to-800-nanometer range, the typical signature of palladium nanostructures, with strong absorption extending into the near-infrared. That combination of high conversion efficiency and good biocompatibility positions PdH simultaneously as a photothermal therapy agent and a photoacoustic imaging agent — the same optical property that lets the sheets heat up enough to release hydrogen and disrupt amyloid aggregates also lets them generate the acoustic waves used to visualize them inside living tissue.

Perhaps the most elegant trick is how the hydrogen gets out. Normally, detecting hydrogen in solution requires platinum nanoparticles as a catalyst; methylene blue, a redox probe, will only register hydrogen’s reducing power with platinum’s help. The PdH sheets dispense with that requirement because they act as a platinum-like autocatalyst themselves, assisting the very hydrogenation reaction that releases their own stored hydrogen. In the methylene blue assay, absorbance plummeted rapidly in the presence of PdH, while pure palladium nanoparticles left the dye essentially untouched over the same reaction period — confirming that palladium alone is not enough and that the hydrogen-loaded hydride form is what actively carries and releases hydrogen. Laser irradiation made things better still: heating the sheets under the 808-nanometer laser further enhanced their reducing power. Complementary radical-scavenging tests reinforced the antioxidant story. In the ABTS assay, the solution progressively decolorized as PdH neutralized ABTS radical cations, with absorbance at 736 nanometers falling in a concentration-dependent manner, and the DPPH assay showed the characteristic purple-to-yellow transition as radicals were quenched at 520 nanometers.

All of this activity is choreographed by imaging. Injected through the tail vein, the nanosheets generated photoacoustic signals in both the first and second near-infrared windows, with the NIR-II window offering more precise localization within the brain and strong guidance for therapy. Paired with second near-infrared fluorescence imaging using an indocyanine-green-labeled formulation, PdH-ICG, the researchers watched fluorescence develop in the brain within two hours of intravenous injection, demonstrating that the sheets readily cross the blood-brain barrier and can be used stably at their target. The authors emphasize that this is where the small size matters most: the barrier is the body’s main obstacle to treating brain disease, and inorganic nanoparticles below roughly 100 nanometers can penetrate a wide range of tissues far more easily than larger carriers. Real-time photoacoustic monitoring means the therapeutic laser is never fired blindly — the operator can first confirm that the agent has accumulated at the lesion, localize the treatment precisely, and use the same signal to evaluate the outcome.

The decisive test came in a mouse model of Alzheimer’s disease. The team injected aggregated amyloid-β 25–35 peptide — aged for seven days at 37 °C to promote fibrillization — into the right lateral ventricle of Balb/c mice via stereotaxic surgery, then split the animals into four groups: healthy wild-type controls given saline, untreated Alzheimer’s mice, mice given PdH alone, and mice given PdH followed by laser. Treated animals received intravenous PdH at 5 milligrams per kilogram every three days for four weeks; the combination group also received 808-nanometer irradiation at 1 watt per square centimeter on the skull surface for five minutes after each injection to trigger on-demand hydrogen release. In the Morris water maze — a 90-centimeter circular pool filled with water held at 24 ± 1 °C, with a 9-centimeter platform hidden one centimeter beneath the surface — all groups learned across five days of training, but the Alzheimer’s mice consistently took far longer to find the platform, and the gap with healthy controls widened as training progressed. PdH alone shortened escape latency. Most strikingly, the PdH-plus-laser group performed at a level comparable to the wild-type animals, which the authors describe as a near-complete restoration of spatial learning. In the day-six probe trial, Alzheimer’s mice swam in aimless, wall-hugging patterns, while the laser-treated mice concentrated their search in the quadrant where the platform had once been, indicating precise spatial memory.

The Y-maze test told the same story: spontaneous alternation — the tendency of a healthy rodent to explore a new arm of the maze rather than revisit the one it just left — was significantly impaired in the Alzheimer’s group compared with wild-type mice, partially rescued by PdH treatment alone, and more robustly reversed by PdH plus laser, bringing alternation percentages back to a level akin to that of normal animals. The authors trace the behavioral rescue to a set of mutually reinforcing mechanisms. The nanosheets enable sustained and light-triggered release of hydrogen, which directly scavenges cytotoxic hydroxyl radicals, easing the oxidative stress and downstream neuroinflammation that drive synaptic dysfunction and memory loss. The photothermal effect does double duty: it accelerates hydrogen release, may contribute directly to the suppression of amyloid-β aggregation, and transiently enhances blood-brain barrier permeability to improve delivery. Photoacoustic guidance keeps the entire sequence precise, ensuring the agents reach their target sites before any therapeutic light is applied.

The researchers are careful about what the results do and do not show. The model relies on injecting pre-aggregated amyloid peptide into the ventricles rather than the slow, whole-body progression of human disease, the behavioral cohorts were small, and moving the platform toward the clinic will require answers to questions the mouse study cannot address: how much near-infrared light can safely reach deep structures through a thicker human skull, how palladium behaves in the brain over months and years, and whether the transient barrier opening carries risks. Even so, the team argues that the demonstration addresses two of the field’s most stubborn challenges at once — getting an active therapy across the blood-brain barrier and intervening against multiple pathological hallmarks simultaneously — and that the approach may open a new window for treating Alzheimer’s disease. The work, funded by science and technology programs of Shanxi Province, suggests that the same logic of image-guided, hydrogen-delivering, light-activated nanomedicine could plausibly extend to other neurodegenerative conditions marked by protein aggregation and oxidative damage.

The innovative concept hinges on the versatility of DNA as a structural molecule. By strategically folding double-stranded DNA into predetermined nanostructures — a technique known as DNA origami — scientists created molecular scaffolds that can carry fluorescent dyes or even anticancer drugs. This molecular origami confers precision at an unprecedented scale, enabling the delivery of imaging agents directly to malignant tissues with minimal interference to surrounding healthy cells. Doing so not only promises to refine tumor visualization during surgery but also opens avenues for targeted chemotherapy with reduced systemic toxicity.

To simulate the complex microenvironment of pancreatic tumors, the research team employed advanced 3D-printed tumoroids coupled with microfluidic tumor-stroma models. These systems replicate the dense stromal architecture intrinsic to pancreatic cancer, providing a refined in vitro platform that diminishes dependence on animal models and accelerates therapeutic validation. The DNA origami structures, infused with imaging dyes, demonstrated remarkable selectivity when introduced to these tumoroids, manifesting robust uptake by KRAS-mutant cancer cells while sparing normal pancreatic tissue.

Beyond the synthetic tumor models, the researchers extended their investigation to in vivo murine models embedded with human pancreatic tumor grafts. Here, fluorescence imaging tracked the biodistribution of the DNA origami nanostructures, affirming their preferential accumulation within malignant tissue. This dual-model approach substantiates the biological relevance and translational potential of DNA origami in clinical oncology, moving one step closer to real-world applications in cancer diagnostics and treatment.

A critical discovery within the study was the influence of the physical parameters of the DNA nanostructures on cellular uptake. The team compared tube-shaped and tile-shaped DNA origami configurations at varying sizes, noting that tube-shaped structures approximately 70 nanometers in length and 30 nanometers in diameter exhibited optimal uptake by pancreatic cancer cells. Smaller tubes around 6 nanometers long and the same diameter also showed significant accumulation. Conversely, larger tubes and all tested tile-shaped molecules failed to replicate this efficient targeting. This observation underscores the intricate interplay between nanostructure morphology and cellular internalization mechanisms.

Professor Bumsoo Han, leading the research, expressed surprise at these findings, emphasizing that uptake is governed by an optimal “sweet spot” in both size and shape that facilitates selective penetration into cancerous cells without affecting normal tissue. This revelation challenges previous assumptions that smaller size uniformly enhances uptake and spotlights the need for precision engineering in the development of nanomedicines.

Looking forward, the research sets the stage for the next generation of therapeutics employing DNA origami as delivery vehicles. By loading these nanoscale frameworks with chemotherapy agents, it is conceivable to administer treatments that concentrate drug effects solely on cancer cells, thereby sparing healthy tissue and reducing adverse side effects. The integration of sophisticated tumor models aims to expedite drug discovery cycles while minimizing reliance on animal testing, aligning with ethical advancements in biomedical research.

The implications of this breakthrough extend beyond pancreatic cancer, heralding a paradigm shift in how molecular imaging and targeted therapy might be approached in various malignancies characterized by dense tumor microenvironments. The precision and programmability of DNA origami nanostructures render them ideally suited for bespoke applications tailored to diverse genetic and anatomical tumor profiles.

This research also highlights the collaborative synergy between engineering and biomedical sciences. By merging mechanical engineering expertise with oncology-focused bioengineering, the team crafted a multidisciplinary strategy that leverages nanoscale manipulation, advanced modeling, and molecular biology to tackle one of medicine’s most intractable diseases. The involvement of prominent facilities like the Carl R. Woese Institute for Genomic Biology and the Beckman Institute underscores the confluence of cutting-edge technology driving this innovation.

Published in the journal Advanced Science, these findings mark a significant stride forward in the molecular imaging field. The study provides robust preclinical evidence that DNA origami can revolutionize how imaging agents and drugs are delivered with cellular and tissue specificity. If translated successfully into clinical practice, such technology could enhance surgeons’ ability to delineate tumor boundaries with exquisite clarity and administer localized chemotherapy with enhanced efficacy.

Moreover, the deployment of 3D printing and microfluidics to engineer tumoroids sets a new standard for modeling human cancers ex vivo. These techniques allow researchers to deconstruct and replicate intricate tumor-stroma interactions in a controlled environment, fostering rapid hypothesis testing and therapeutic optimization. This is particularly valuable in diseases like pancreatic cancer, where traditional models have fallen short in mimicking the fibrotic milieu that impairs drug penetration.

Funding from the National Institutes of Health and the National Science Foundation has been instrumental in supporting this endeavor. Such backing also emphasizes the prioritization of interdisciplinary research initiatives that merge nanotechnology, oncology, and engineering to confront complex health challenges. Professor Han, alongside collaborators at Purdue and affiliated research institutes, continues to pioneer advancements aimed at refining diagnostic precision and therapeutic targeting through nanoscale design.

The clinical translation of DNA origami technology promises a future where pancreatic cancer patients might benefit from enhanced surgical outcomes and tailored chemotherapy regimens with fewer side effects. While early-stage, this research lays the groundwork for innovative therapies that exploit molecular self-assembly principles to overcome existing barriers in cancer care.

As the research community eagerly anticipates further developments, the extraordinary specificity and versatility of DNA origami nanostructures stand as a beacon for the future of precision medicine. Their capacity to interface at the molecular level with diseased cells, combined with the adaptability to carry diverse functional cargoes, positions them as a transformative tool in the battle against pancreatic and other aggressive cancers.

Subject of Research: Cells

Article Title: DNA origami-cyanine nanocomplex for precision imaging of KRAS-mutant pancreatic cancer cells

News Publication Date: 14-Feb-2025

Web References:
https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202410278

References:
Han, B., Choi, J.H., et al. “DNA origami-cyanine nanocomplex for precision imaging of KRAS-mutant pancreatic cancer cells.” Advanced Science, DOI: 10.1002/advs.202410278.

Image Credits:
Photo by Fred Zwicky

Keywords: Pancreatic cancer, DNA origami, KRAS mutation, fluorescent imaging, nanotechnology, tumor microenvironment, 3D tumoroids, microfluidics, targeted therapy, molecular imaging, nanomedicine, tumor-stroma model